Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome

NCT00004918 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

69

Enrollment

NIH

Sponsor class

Conditions

Accelerated Phase Chronic Myelogenous Leukemia
Adult Acute Myeloid Leukemia in Remission
Chronic Phase Chronic Myelogenous Leukemia
Previously Treated Myelodysplastic Syndromes
Refractory Anemia With Excess Blasts
Refractory Anemia With Excess Blasts in Transformation
Relapsing Chronic Myelogenous Leukemia

Interventions

BIOLOGICAL: PR1 leukemia peptide vaccine
DRUG: Montanide ISA 51 VG
BIOLOGICAL: sargramostim
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)